No association of CSF biomarkers with APOEε4, plaque and tangle burden in definite Alzheimer's disease
暂无分享,去创建一个
Christine Van Broeckhoven | Sebastiaan Engelborghs | Eugeen Vanmechelen | Kristel Sleegers | P. Deyn | C. Broeckhoven | K. Sleegers | S. Engelborghs | S. Serneels | E. Vanmechelen | P. Cras | N. Brouwers | Jean-Jacques Martin | Nathalie Brouwers | Sally Serneels | Peter Paul De Deyn | Jean-Jacques Martin | Patrick Cras | Evelyn De Leenheir
[1] A. Hofman,et al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. , 1998, Archives of neurology.
[2] K. Blennow,et al. CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study , 2003, Neurology.
[3] Lisheng Cai,et al. Imaging and In Vivo Quantitation of β-Amyloid: An Exemplary Biomarker for Alzheimer’s Disease? , 2006, Biological Psychiatry.
[4] H. Braak,et al. Neuropathology of Alzheimer’s disease: what is new since A. Alzheimer? , 1999, European Archives of Psychiatry and Clinical Neuroscience.
[5] K. Blennow,et al. Increased levels of CSF phosphorylated tau in apolipoprotein E epsilon4 carriers with mild cognitive impairment. , 2005, Neuroscience letters.
[6] W. Markesbery. Neuropathology of dementing disorders , 1998 .
[7] H. Vanderstichele,et al. Cerebrospinal beta-amyloid (1–42) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline , 2000, Neuroscience Letters.
[8] A. Nordberg,et al. Cerebral glucose metabolism, cerebrospinal fluid-β-amyloid1–42 (CSF-Aβ42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients , 2003, Neuroscience Letters.
[9] P. Mehta,et al. The effects of age, apolipoprotein E phenotype and gender on the concentration of amyloid-β (Aβ) 40, Aβ42, apolipoprotein E and transthyretin in human cerebrospinal fluid , 1998 .
[10] L. Wahlund,et al. Cerebrospinal Fluid Tau Levels Increase with Age in Healthy Individuals , 2001, Dementia and Geriatric Cognitive Disorders.
[11] J. Haines,et al. Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .
[12] T. Sunderland,et al. Apolipoprotein E ϵ4 allele in association with global cognitive performance and CSF markers in Alzheimer's disease , 1998, International journal of geriatric psychiatry.
[13] P. Mehta,et al. The effects of age, apolipoprotein E phenotype and gender on the concentration of amyloid-beta (A beta) 40, A beta 4242, apolipoprotein E and transthyretin in human cerebrospinal fluid. , 1998, Clinical biochemistry.
[14] A Drzezga,et al. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. , 2002, Archives of neurology.
[15] K. Blennow,et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.
[16] K Kontula,et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. , 1995, The New England journal of medicine.
[17] K. Blennow,et al. CSF levels of tau, β-amyloid1–42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging , 2000, Journal of Neural Transmission.
[18] Kaj Blennow,et al. Cerebrospinal fluid levels of total‐tau, phospho‐tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment , 2003 .
[19] R. Wolfert,et al. Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease , 1995 .
[20] P. Deyn,et al. Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF , 1999, Neurology.
[21] H. Soininen,et al. The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease , 1997, Neuroreport.
[22] J. Haines,et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.
[23] Hilkka Soininen,et al. Relationship between apoE genotype and CSF β-amyloid (1–42) and tau in patients with probable and definite Alzheimer’s disease , 2000, Neurobiology of Aging.
[24] Kaj Blennow,et al. Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients , 2003, Neuroscience Letters.
[25] M. Cruts,et al. Cerebral amyloid angiopathy is a pathogenic lesion in Alzheimer's disease due to a novel presenilin 1 mutation. , 2001, Brain : a journal of neurology.
[26] J. Kaye,et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. , 1998, Archives of neurology.
[27] K. Blennow,et al. Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies , 2006, Clinical chemistry and laboratory medicine.
[28] B. Winblad,et al. Assessments of the accumulation severities of amyloid β-protein and hyperphosphorylated tau in the medial temporal cortex of control and Alzheimer's brains , 2006, Neurobiology of Disease.
[29] Holly Soares,et al. Cerebrospinal fluid β-amyloid1–42 and tau in control subjects at risk for Alzheimer’s disease: The effect of APOE ε4 allele , 2004, Biological Psychiatry.
[30] Henrik Zetterberg,et al. APOE ε4 allele is associated with reduced cerebrospinal fluid levels of Aβ42 , 2004, Neurology.
[31] Margaret A. Pericak-Vance,et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease , 1997 .
[32] H. Braak,et al. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry , 2006, Acta Neuropathologica.
[33] H. Wiśniewski,et al. Plasma and cerebrospinal fluid Levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease , 2000 .
[34] K. Jellinger,et al. The neuropathological diagnosis of Alzheimer disease. , 1998, Journal of neural transmission. Supplementum.
[35] M. Cruts,et al. Molecular genetic analysis of familial early-onset Alzheimer's disease linked to chromosome 14q24.3. , 1995, Human molecular genetics.
[36] H. Soininen,et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. , 2006, Brain : a journal of neurology.
[37] K. Blennow,et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. , 1999, Archives of neurology.
[38] Henrik Zetterberg,et al. Cerebrospinal fluid markers for prediction of Alzheimer's disease , 2003, Neuroscience Letters.
[39] J. Morris,et al. Relationships Among Cerebrospinal Fluid Biomarkers in Dementia of the Alzheimer Type , 2002, Alzheimer disease and associated disorders.
[40] K. Blennow,et al. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease , 2005, Clinical Neurology and Neurosurgery.
[41] K. Blennow,et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. , 2001, Archives of neurology.
[42] Holly Soares,et al. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. , 2004, Biological psychiatry.
[43] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[44] H. Kretzschmar,et al. Brain-derived proteins in the CSF, do they correlate with brain pathology in CJD? , 2006, BMC neurology.